Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

ajmc.com image

News from ajmc.com

See all of ajmc.com news coverage in one place. Discover how ajmc.com’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve aggregated 917 of ajmc.com’s headlines and news stories over the past 3 months.

ajmc.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

ajmc.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about ajmc.com

Where is ajmc.com located?ajmc.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ajmc.com News

Johnson & Johnson's Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma

Johnson & Johnson · United States

Johnson & Johnson's Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma

56% Center coverage: 9 sources

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease See the Story

Goal to end AIDS by 2030 ’more off-track’ after Trump cuts, UNAIDS head says

Goal to end AIDS by 2030 ’more off-track’ after Trump cuts, UNAIDS head says

43% Right coverage: 7 sources

By Tim Cocks See the Story

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Merck & Co (NYSE:MRK)

Cancer · United States

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Merck & Co (NYSE:MRK)

100% Center coverage: 3 sources

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (combined positive score of at least 1), as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent…See the Story

Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

100% Center coverage: 2 sources

(MedPage Today) -- The FDA approved taletrectinib (Ibtrozi) -- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)...Pharma · United States See the Story

Sasanlimab Plus BCG in BCG-Naive, High-Risk Non-Muscle Invasive Bladder Cancer: the Randomized Phase 3 CREST Trial

100% Center coverage: 2 sources

Bacillus Calmette–Guérin (BCG) induction and maintenance (I+M) after transurethral resection of bladder tumor is standard of care (SOC) in high-risk non-muscle invasive bladder cancer (NMIBC). However, disease recurrence/progression occurs in approximately 40% of patients at 2 years, with unfavorable prognosis. Limited bladder-sparing therapeutic options exist, and no improvements to response durability have been observed in decades. CREST is a …United States · United States See the Story

Discussing Sexuality, Mental Health With AYA Patients Amid the Hematological Treatment Journey

Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary strategy to ensure their mental and sexual well-being during and beyond treatment, clinicians and patients agreed.Mental Health · United States Read Article

Phase 3 POLARGO Trial Shows Survival Benefit of Polatuzumab-Based Regimen in R/R DLBCL: Matthew Matasar, MD

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), according to Matthew Matasar, MD, of Rutgers Cancer institute.Maryland · Maryland Read Article

Phase 3 IRAKLIA Trial Compares On-Body vs IV Isatuximab in RRMM: Xavier Leleu, MD, PhD

The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma (RRMM).Maryland · Maryland Read Article

EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures

Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.Belgium · Belgium Read Article

Lower Socioeconomic Status Tied to Worse Quality of Life in R/R Multiple Myeloma: Francesco Sparano, MSc

Patients with relapsed/refractory (R/R) multiple myeloma and lower socioeconomic status reported significantly worse quality of life and a higher burden of symptoms, according to Francesco Sparano, MSc, of the GIMEMA Foundation.Read Article

AI-Derived Therapy for IPF Shows Potential in Phase 2a Trial

The potential therapy for idiopathic pulmonary fibrosis is notable because not only was the small molecule discovered by artificial intelligence, but the drug’s target itself was, too.Artificial Intelligence Read Article

Breaking News Topics Related to ajmc.com